Biography

Dr Anna Bateson has been at UCL Centre for Clinical Microbiology since 2007, involved in TB Clinical Trials working primarily with the TB Alliance (REMoxTB, Nix, ZeNix, STAND, NC007, NC008, NC009), but also Medicins Sans Frontier (TB-Practecal), and UCL (UNITE4TB). This has involved both oversight of the UCL Central Laboratory where MTB drug susceptibility testing and whole genome sequencing is performed; and laboratory monitoring activities that ensure high quality microbiology data at local clinical trial laboratories. Dr. Bateson previously obtained a PhD from London School of Hygiene and Tropical Medicine.

Expertise

TB Diagnostics
Public Health

Key Impacts

Baseline and acquired resistance-associated M. tuberculosis variants in BPaL-based regimens

Baseline-resistance rates to all drugs in the BPaL-based regimens, except moxifloxacin, were very low. Acquired resistance was observed to bedaquiline and clofazimine, albeit at very low rates.

Source: Conference 2024